The abstract is read at the publisher; the summary is JClub's.
Reporting in randomized adjuvant systemic therapy trials should quantify the proportion of treated patients with prespecified HRQOL deterioration and its duration, using validated scales.
- Why it matters: Adjuvant therapy can add side-effects that impair health-related quality of life, while survival benefits may be small, making patient functioning and symptom burden central to decisions.
- What they did: Common-Sense Oncology and EORTC recommend publishing deterioration proportions on relevant HRQOL scales, including symptoms, functioning domains, and overall HRQOL, with methods for missing data and intercurrent events.
- The result: This approach enables clear between-group HRQOL comparisons and identification of patient subgroups at higher risk, supporting informed treatment choice and long-term follow-up for lasting deficits.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.